In a regulatory filing, Piramal Pharma stated that the observations primarily relate to procedural improvements and are not linked to data integrity. The company is preparing a detailed response and plans to submit it within the stipulated timeframe.
“The observations are largely related to the improvement of procedures and practices, and not to data integrity. The company is preparing a detailed response to the said observations, which will be submitted to the agency within the stipulated timelines,” Piramal Pharma said. The company reaffirmed its commitment to maintaining high compliance standards and expressed confidence in addressing the observations effectively.
Also Read: Hexaware Technologies IPO listing today. What GMP signals ahead of debut?
Piramal Pharma Q3 earnings
Piramal Pharma reported a net profit of Rs 4 crore in Q3FY25, compared to Rs 10 crore in the same quarter last year. Revenue from operations grew 13% year-on-year (YoY) to Rs 2,204 crore in Q3FY25. EBITDA rose 6% YoY to Rs 350 crore, while EBITDA margins fell by 100 basis points to 16%.
Also Read: Stocks in news: Vedanta, RVNL, Max Healthcare Institute, Allcargo Gati and Affordable Robotic
Piramal Pharma shares target price
According to Trendlyne data, the average target price of the stock is Rs 306, implying an upside of 55% from the current market prices. The consensus recommendation from 7 analysts for the stock is a ‘Strong Buy.’
Piramal Pharma shares performance
On Tuesday, Piramal Pharma shares closed at Rs 197, down 1.1% on the BSE, while the benchmark Sensex declined by 0.04%. The stock has declined 22% in the past three months but surged 47% in the last 12 months. The company’s market capitalization stands at Rs 26,203 crore.
Also Read: FII selling likely to subside from April, Nifty can touch 25,000 by Dec: Emkay
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
